Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study

(University of Texas M. D. Anderson Cancer Center) A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news